Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Calabrese

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Italian Journal of Dermatology and Venereology|October 3, 2025
Dermatological adverse events during hematological and oncological therapies (Bruton's tyrosine kinase inhibitors and mogamulizumab): an Italian retrospective multicenter studyMichela Starace, Stephano Cedirian, Luca Rapparini, et al.
Italian Journal of Dermatology and Venereology|January 12, 2026
T2-Reg: a regional web registry on Th2-mediated diseasesMartina D'Onghia, Giovanni Rubegni, Flavia Manzo Margiotta, et al.
Antibodies (Basel, Switzerland)|September 22, 2025
Safety and Effectiveness of Dupilumab in Atopic Dermatitis Patients with Hematologic Comorbidities: A Multicenter, Retrospective StudyLuca Bettolini, Stefano Bighetti, Silvia Mariel Ferrucci, et al.
Acta Dermato-Venereologica|June 30, 2026
Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of PatientsAnna Pira, Martina Merli, Feliciana Mariotti, et al.
Journal of Clinical Medicine|June 26, 2026
The Early Implementation of a Hub-and-Spoke Survivorship Pathway for Out-of-Hospital Cardiac Arrest Survivors: A 12-Month Formative Evaluation of the REVIVE ProjectLaura Calabrese, Marco Mion, Alice Mandrini, et al.
Clinical and Experimental Rheumatology|May 8, 2026
Correction to: IL-1 targeting agents in Schnitzler syndrome: a multicentre, real-world study from the international AIDA Network Schnitzler RegistryLaura Calabrese, Alessandra Cartocci, Antonio Vitale, et al.
Clinical and Experimental Rheumatology|October 24, 2025
IL-1 targeting agents in Schnitzler syndrome: a multicentre, real-world study from the international AIDA Network Schnitzler RegistryLaura Calabrese, Alessandra Cartocci, Antonio Vitale, et al.
Clinical and Experimental Dermatology|July 15, 2025
Therapeutic Outcomes Across JAK Inhibitors in Prurigo NodularisGianluca Avallone, Andrea Bombelli, Luca Valtellini, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|November 7, 2025
<i>Letter:</i> Optimizing Dupilumab Dosing in Atopic Dermatitis: Real-World EvidenceFrancesca Barei, Paolo Calzari, Stefano Macchi, et al.
International Journal of Dermatology|August 21, 2025
Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective StudyLuca Potestio, Cataldo Patruno, Marika Del Gaudio, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Italian Journal of Dermatology and Venereology|October 3, 2025
Dermatological adverse events during hematological and oncological therapies (Bruton's tyrosine kinase inhibitors and mogamulizumab): an Italian retrospective multicenter studyMichela Starace, Stephano Cedirian, Luca Rapparini, et al.
Italian Journal of Dermatology and Venereology|January 12, 2026
T2-Reg: a regional web registry on Th2-mediated diseasesMartina D'Onghia, Giovanni Rubegni, Flavia Manzo Margiotta, et al.
Antibodies (Basel, Switzerland)|September 22, 2025
Safety and Effectiveness of Dupilumab in Atopic Dermatitis Patients with Hematologic Comorbidities: A Multicenter, Retrospective StudyLuca Bettolini, Stefano Bighetti, Silvia Mariel Ferrucci, et al.
Acta Dermato-Venereologica|June 30, 2026
Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of PatientsAnna Pira, Martina Merli, Feliciana Mariotti, et al.
Journal of Clinical Medicine|June 26, 2026
The Early Implementation of a Hub-and-Spoke Survivorship Pathway for Out-of-Hospital Cardiac Arrest Survivors: A 12-Month Formative Evaluation of the REVIVE ProjectLaura Calabrese, Marco Mion, Alice Mandrini, et al.
Clinical and Experimental Rheumatology|May 8, 2026
Correction to: IL-1 targeting agents in Schnitzler syndrome: a multicentre, real-world study from the international AIDA Network Schnitzler RegistryLaura Calabrese, Alessandra Cartocci, Antonio Vitale, et al.
Clinical and Experimental Rheumatology|October 24, 2025
IL-1 targeting agents in Schnitzler syndrome: a multicentre, real-world study from the international AIDA Network Schnitzler RegistryLaura Calabrese, Alessandra Cartocci, Antonio Vitale, et al.
Clinical and Experimental Dermatology|July 15, 2025
Therapeutic Outcomes Across JAK Inhibitors in Prurigo NodularisGianluca Avallone, Andrea Bombelli, Luca Valtellini, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|November 7, 2025
<i>Letter:</i> Optimizing Dupilumab Dosing in Atopic Dermatitis: Real-World EvidenceFrancesca Barei, Paolo Calzari, Stefano Macchi, et al.
International Journal of Dermatology|August 21, 2025
Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective StudyLuca Potestio, Cataldo Patruno, Marika Del Gaudio, et al.
Pageof 8